

FROM THEORY TO PRACTICE:

Implementing the EU Health Technology Assessment Regulation



HYBRID MEETING – UTRECHT, THE NETHERLANDS, 30 JANUARY 2024

PROGRAMME

All times indicated in this programme are in CET.

09:00 – 09:15 Welcome and introduction by **Tamsin Rose**, Moderator.

Welcome by **Sjaak Wijma**, CEO of the National Health Care Institute, The Netherlands.

Video message from **Sandra Gallina**, Director General of the Directorate General for Health and Food Safety, European Commission

09:15 – 10:00 Presentation and Q&A: “The EU regulation on health technology assessment: what’s in it and why it matters?”

- **Roisin Adams**, Chair of the Member State Coordination Group on HTA
- **Anne Willemsen**, Co-chair of the subgroup for joint clinical assessments
- **Valentina Barbuto**, Directorate-General for Health and Food Safety, European Commission

10:00 – 10:50 Panel discussion: “The national perspective - Expectations, opportunities and the challenges ahead”

- **Susanne Zöhrer**, Ministry of Health, Austria
- **Marc Van De Castele**, National Institute for Health and Disability Insurance, Belgium
- **Emer Fogarty**, National Centre for Pharmacoeconomics, Ireland
- **Magali Boers**, Ministry of Health, Luxembourg
- **Lonneke Timmers**, National Health Care Institute, The Netherlands

Q&A and views from stakeholders

10:50 – 11:10 Coffee break

11:10 – 11:55 Panel discussion: “Ensuring engagement and cooperation in joint clinical assessments”

- **Anna Nachtnebel**, Austrian Social Insurance
- **Marijke de Vries**, National Health Care Institute, The Netherlands
- **Robin Doeswijk**, European Hematology Association
- **Derick Mitchell**, IPPOSI - The Irish Platform for Patient Organisations, Science and Industry
- **Marjan Willaert**, Pharma.be – Association of the Medicines Industry, Belgium

Q&A and views from stakeholders

FROM THEORY TO PRACTICE:

Implementing the EU Health Technology Assessment Regulation

11:55 – 12:40 Panel discussion: “Ensuring engagement and cooperation in joint scientific consultations”

- **Simon Roels**, National Institute for Health and Disability Insurance, Belgium
- **Dominique Hamerlijnck**, Dutch Lung Foundation, The Netherlands
- **Barbara Claus**, Ghent University Hospital, Belgium
- **Michael Berntgen**, European Medicines Agency

Q&A and views from stakeholders

12:40 – 12:45 Closing remarks by:

- **Tamsin Rose**, Moderator
 - **Roisin Adams**, Chair of the Member State Coordination Group on HTA
-

To join the Slido poll or submit questions and comments via Slido, please follow this [link](#), or scan the QR code:

